Posted by Michael Wonder on 29 Jan 2019
UPMC Health Plan announces innovative, value-based agreement with AstraZeneca
28 January 2019 - Value-based contract for Brilinta (ticagrelor) improves member access to the medicine and uniquely includes two-sided financial risk.
UPMC Health Plan and AstraZeneca today announced the initiation of a pioneering value-based contract effective 1 January 2019 for UPMC for Life Medicare members who are prescribed Brilinta (ticagrelor), a medication used to lower a patient's chances of having another heart attack or dying from one in the 12 months following a heart attack.
The goal of the contract is to align the incentives of the manufacturer, AstraZeneca, with UPMC Health Plan by connecting reimbursement for Brilinta to clinical outcomes in a real-world population. Specifically, reimbursement for the medication will be linked to cardiovascular outcomes for people treated with Brilinta following a recent hospitalisation for heart attack or unstable angina.
